Patients with spinal cord injury have a high prevalence of osteoporosis due to chronic skeletal unloading. Recently, various treatment drugs for osteoporosis have been developed. In particular, romosozumab, a sclerostin inhibitor, has been reported to have a high therapeutic effect as an inhibitor of bone resorption while promoting bone formation. However, there are a few research concerning sclerostin of spinal cord injuries patients. Therefore we want to analyze the change of sclerostin as well as factors indicating bone formation and absorption marker in spinal cord injury patient.

Inclusion Criteria:

• spinal cord injury patients
• Functional ambulatory category index of 3 or less

Exclusion Criteria:

• history of using bone absorption medication within the effective period

Patients with spinal cord injury difficult to walk